Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03025360 |
Expanded Access Status :
Approved for marketing
First Posted : January 19, 2017
Last Update Posted : December 19, 2019
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Larotrectinib expanded access is for patients with cancer with a NTRK1, NTRK2, or NTRK3 gene fusion, who are ineligible for an ongoing larotrectinib clinical trial or have other considerations that prevent access to larotrectinib through an existing clinical trial. Gene fusion occurs when a gene is made by joining parts of two different genes. NTRK gene fusion can lead to the development of solid tumors in a variety of tissue types. The study drug larotrectinib blocks the action of the NTRK gene fusion.
Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion who are unresponsive to current standard treatment for their condition and also are unable to participate in ongoing clinical trials.
Condition or disease | Intervention/treatment |
---|---|
Tumors Harboring NTRK Fusion | Drug: Larotrectinib (Vitrakvi, BAY2757556) |
Study Type : | Expanded Access |
Expanded Access Type : | Individual Patients |
See clinical trials of the intervention/treatment in this expanded access record. | |
Official Title: | Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion |
- Drug: Larotrectinib (Vitrakvi, BAY2757556)
Larotrectinib will be administered orally as capsule or liquid solution as specified by the treating physician.Other Name: LOXO-101
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of cancer with a NTRK1, NTRK2, or NTRK3 gene fusion
- Subjects are unable to participate in an ongoing larotrectinib clinical trial
- Medically suitable for treatment with larotrectinib
Exclusion Criteria:
- Currently enrolled in an ongoing clinical study of larotrectinib or another TRK inhibitor
Responsible Party: | Bayer |
ClinicalTrials.gov Identifier: | NCT03025360 |
Other Study ID Numbers: |
20366 |
First Posted: | January 19, 2017 Key Record Dates |
Last Update Posted: | December 19, 2019 |
Last Verified: | December 2019 |
Neurotrophic tyrosine receptor kinase (NTRK) NTRK1 NTRK2 NTRK3 Fusion Positive |